✦ LIBER ✦

Naloxone in tardive dyskinesia

✍ Scribed by I. Blum; P. F. Nisipeanu; E. Roberts

Publisher: Springer
Year: 1987
Tongue: English
Weight: 90 KB
Volume: 93
Category: Article
ISSN: 0033-3158
DOI: 10.1007/bf00207250

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The opiate antagonist naloxone suppresse

The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia

✍ Dr. A. Jon Stoessl; Elizabeth Polanski; Hanna Frydryszak 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 778 KB

## Abstract The effects of both opiate agonists and the opiate antagonist naloxone were examined in a rodent model of tardive dyskinesia (TD). Chronic (˜20 weeks) administration of fluphenazine resulted in the emergence of vacuous chewing mouth movements (VCMs), a response which may be a useful mod

Bereitschaftspotential in tardive dyskin

Bereitschaftspotential in tardive dyskinesia

✍ Dr. Lawrence E. Adler; Mark Pecevich; Herbert Nagamoto 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 518 KB

The bereitschaftspotential or motor readiness potential is a slow negative electroencephalographic wave occurring 150-1500 ms prior to the onset of a voluntary movement. It was measured in 33 subjects: 11 normal controls, 11 medicated schizophrenics with no tardive dyskinesia or evidence of drug-ind

Clozapine in tardive dyskinesia

✍ George M. Simpson; J. Hillary Lee; Ram K. Shrivastava 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 468 KB

Sulpiride in tardive dyskinesia

✍ Daniel E. Casey; Jes Gerlach; Hans Simmelsgaard 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 407 KB

Tardive dyskinesia can be suppressed by drugs that block dopaminergic receptors, but often at the cost of a concomitant increase in parkinsonism. Sulpiride (400 -- 2100 mg/day), a selective type-2 dopamine receptor antagonist, was evaluated in a blind, placebo-controlled trial in 11 patients with ta

Laryngeal tardive dyskinesia

✍ A. Féve; B. Angelard; J. Lacau St Guily 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 418 KB

Butaperazine pharmacokinetics in tardive

Butaperazine pharmacokinetics in tardive dyskinesia

✍ Dr. Marion E. Wolf; Javaid I. Javaid; Aron D. Mosnaim; John M. Davis 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

failed to show any significant differences in the steady-state serum levels of thioridazine or its metabolites between TD and non-TD schizophrenic subjects.